Any rapid weight-loss method carries a risk of muscle loss, but GLP-1 medications amplify it because patients eat much less spontaneously
Treatment with insulin detemir as add-on to liraglutide injection 1.8 mg + metformin resulted in statistically significant reductions in HbA1c and FPG compared to continued, unchanged treatment with liraglutide injection 1.8 mg + metformin alone (Table 6)
translation to dogs is uncertain Lack of clinical trials: No published randomized controlled trials in dogs Regulatory status: Not approved by FDA or veterinary regulatory agencies Quality control: Variability in peptide quality from research suppliers Optimal protocols: Dose, frequency, duration, and timing relative to injury not established for dogs Outcome measures: Standardized assessment of improvement in dogs lacking Long-term effects: Unknown effects of chronic use in companion animals Complementary Approaches to Canine Orthopedic Care Established evidence-based interventions for canine orthopedic conditions include: Weight management: Critical for reducing joint stress and improving outcomes Physical rehabilitation: Therapeutic exercises, hydrotherapy, and passive range of motion NSAIDs: Carprofen, meloxicam, and other veterinary anti-inflammatories Joint supplements: Glucosamine, chondroitin sulfate, omega-3 fatty acids Regenerative medicine: Platelet-rich plasma (PRP), stem cell therapy Surgical interventions: Various procedures depending on specific condition Assistive devices: Braces, slings, carts for mobility support Acupuncture and laser therapy: Adjunctive pain management modalities The Veterinary Research Landscape Peptide research in veterinary medicine faces unique challenges: Limited funding compared to human medical research Smaller market size for veterinary pharmaceuticals Regulatory pathways less established than for human drugs Ethical considerations for experimental treatments in companion animals Need for breed-specific and size-specific data given canine diversity Despite these challenges, there is growing interest in translating peptide research to veterinary applications, particularly for conditions with limited treatment options
This proposed concept mirrors forward genetics, we know the external phenotype is melanoma, therefore doing a high throughput un-biased screen for serum biomarkers will reveal expression changes of biomarkers between healthy controls, disease-free patients, and melanoma patients, which will provide insights into key driver pathways regulating metastasis
Patients who have experienced anaphylaxis or angioedema with tirzepatide should not be rechallenged with the medication
